Zhan Hui-Qin, Zhou Ji-Lin, Zhang Jun, Wu De, Gu Chun-Yan
Department of Ophthalmology, The Third People's Hospital of Changzhou, Changzhou 213001, Jiangsu Province, China.
World J Diabetes. 2023 Aug 15;14(8):1271-1279. doi: 10.4239/wjd.v14.i8.1271.
The prevalence of diabetes mellitus (DM) in China is high, and the base is broad. Diabetic retinopathy (DR) is a critical condition affecting the life and health of a nation and its economic development. DR is a common complication of DM.
To investigate the efficacy of laser photocoagulation combined with intravitreal injection of conbercept for treating macular edema.
Overall, 130 patients with diabetic macular edema (DME) hospitalized in The Third People's Hospital of Changzhou from January 2019 to June 2022 were retrospectively included. According to the treatment plan, 130 patients with DME were categorized into an observation and a control group, with 65 patients in each group. The control group received laser photocoagulation, and the observation group received laser photocoagulation with intravitreal injection of conbercept. Observe changes in vision, cytokines in the eye and so on.
The total efficacy rate in the observation group (93.85%) was higher than that in the control group (78.46%) ( 0.05). In both groups, the best corrected visual acuity correction effect improved after treatment, and the observation group was superior to the control group 0.05). Retinal thickness and central macular thickness improved after treatment, and the observation group was superior to the control group < 0.05). The levels of vascular endothelial growth factor, interleukin-6, soluble intercellular adhesion molecule-1, and basic fibroblast growth factor in both groups improved after treatment, and the observation group was superior to the control group < 0.05).
In patients with macular edema, combining laser photocoagulation and intravitreal injections of conbercept for DME is a more effective and safer strategy to improve vision, and lower intraocular cytokine levels.
中国糖尿病（DM）患病率高，基数大。糖尿病视网膜病变（DR）是影响国民生活健康和经济发展的关键病症。DR是DM的常见并发症。
探讨激光光凝联合玻璃体内注射康柏西普治疗黄斑水肿的疗效。
回顾性纳入2019年1月至2022年6月在常州市第三人民医院住院的130例糖尿病黄斑水肿（DME）患者。根据治疗方案，将130例DME患者分为观察组和对照组，每组65例。对照组接受激光光凝治疗，观察组接受激光光凝联合玻璃体内注射康柏西普治疗。观察视力、眼内细胞因子等变化。
观察组总有效率（93.85%）高于对照组（78.46%）（P<0.05）。两组治疗后最佳矫正视力均有改善，且观察组优于对照组（P<0.05）。治疗后视网膜厚度和黄斑中心厚度均有改善，且观察组优于对照组（P<0.05）。两组治疗后血管内皮生长因子、白细胞介素-6、可溶性细胞间黏附分子-1和碱性成纤维细胞生长因子水平均有改善，且观察组优于对照组（P<0.05）。
对于黄斑水肿患者，激光光凝联合玻璃体内注射康柏西普治疗DME是一种更有效、更安全的改善视力和降低眼内细胞因子水平的策略。
